Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC

Introduction: Checkpoint inhibitor pneumonitis (CIP) is a serious toxicity of anti–programmed death-(ligand) 1 immunotherapy. Whether pretreatment differences in pulmonary function exist in patients who develop CIP is unknown. We analyzed the pulmonary function tests (PFTs) of patients with NSCLC tr...

Full description

Bibliographic Details
Main Authors: Joshua E. Reuss, MD, Emily Brigham, MD, MHS, Kevin J. Psoter, PhD, Khinh Ranh Voong, MD, Bairavi Shankar, BS, David S. Ettinger, MD, Kristen A. Marrone, MD, Christine L. Hann, MD, Benjamin Levy, MD, Josephine L. Feliciano, MD, Julie R. Brahmer, MD, David Feller-Kopman, MD, Andrew D. Lerner, MD, Hans Lee, MD, Lonny Yarmus, DO, Russell K. Hales, MD, Franco D’Alessio, MD, Sonye K. Danoff, MD, PhD, Patrick M. Forde, MBBCH, Karthik Suresh, MD, Jarushka Naidoo, MBBCH, MHS
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small cell lung cancer
Pneumonitis
Pulmonary function tests
Immune checkpoint inhibitor
Immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000795

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000795

Similar Items